Display options
Cite
Hidalgo Grau LA, Badia JM, Salvador CA, et al. Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB (Oxford). 2004;6(3):174-80doi: 10.1080/13651820410025110.
Hidalgo Grau, L. A., Badia, J. M., Salvador, C. A., Monsó, T. S., Canaleta, J. F., Nogués, J. M., & Sala, J. S. (2004). Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB : the official journal of the International Hepato Pancreato Biliary Association, 6(3), 174-80. https://doi.org/10.1080/13651820410025110
Hidalgo Grau, Luis A, et al. "Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. 6,3 (2004): 174-80. doi: https://doi.org/10.1080/13651820410025110
Hidalgo Grau LA, Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogués JM, Sala JS. Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB (Oxford). 2004;6(3):174-80. doi: 10.1080/13651820410025110. PMID: 18333072; PMCID: PMC2020674.
Copy Download .nbib Format: NLM
Share it on

HPB (Oxford). 2004;6(3):174-80. doi: 10.1080/13651820410025110.

Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Luis A Hidalgo Grau, Josep M Badia, Carmen Admella Salvador, Teresa Soler Monsó, Josep Feliu Canaleta, Josep M Gubern Nogués, Javier Suñol Sala

Affiliations

  1. Department of General Surgery, Hospital de Matarró, Barcelona, Spain. [email protected]

PMID: 18333072 PMCID: PMC2020674 DOI: 10.1080/13651820410025110

Abstract

BACKGROUND: The overexpression of p53 protein and the expression of Ki-67 antigen may affect the survival of patients with gallbladder carcinoma. This association has been tested in a series of 41 patients with relatively early carcinoma of the gallbladder.

METHODS: Forty-one surgical specimens from patients with a postoperative histological diagnosis of gallbladder carcinoma were studied. All patients were operated by simple cholecystectomy only because the tumours were not advanced and/or their general condition was poor. Patients submitted to radical operations were excluded. p53 expression was calculated from nuclear staining according to the intensity and extent of positive cells, as graded on a scale from 1 to 3; a combined score of >3 was considered as overexpression. Ki-67 expression was calculated by the MIB-I index: the percentage of positively stained tumour cell nuclei out of the total tumour cells counted (n = 1000); >20% of stained cells was considered positive.

RESULTS: Twenty-nine gallbladder carcinomas (71%) overexpressed p53 protein in the cell nuclei. No significant differences were found in relation to cell differentiation on the level of tumour infiltration through the gallbladder wall. Five-year survival of patients with gallbladder carcinoma overexpressing p53 was 17.2%, while survival of patients without p53 overexpression was 30% (not significant). Twenty-four cases (58.5%) were considered positive for the MIB-I index. There were no differences between the grade of cell differentiation and wall infiltration. Five-year survival of the patients with a MIB-I positive index was 9.2% as opposed to 27.7% for those with a negative index (not significant).

CONCLUSIONS: p53 protein nuclear overexpression and Ki-67 protein expression in gallbladder carcinoma were not related to histological differentiation, level of gallbladder wall invasion or patient survival.

References

  1. Am J Pathol. 1989 Apr;134(4):733-9 - PubMed
  2. Oncol Rep. 2001 Sep-Oct;8(5):1127-32 - PubMed
  3. Eur J Surg Oncol. 2000 Mar;26(2):164-7 - PubMed
  4. Cancer Res. 1994 Aug 15;54(16):4342-6 - PubMed
  5. Cancer Res. 1994 Sep 15;54(18):4855-78 - PubMed
  6. Cancer. 1996 Nov 1;78(9):1881-7 - PubMed
  7. N Engl J Med. 1994 Nov 10;331(19):1259-64 - PubMed
  8. Pathol Int. 1997 Aug;47(8):525-30 - PubMed
  9. Science. 1991 May 3;252(5006):706-9 - PubMed
  10. Cancer. 1999 Jan 15;85(2):318-25 - PubMed
  11. Am J Pathol. 1991 Jun;138(6):1471-7 - PubMed
  12. Hum Pathol. 1994 Sep;25(9):929-35 - PubMed
  13. Hum Pathol. 1996 Apr;27(4):360-5 - PubMed
  14. Hum Pathol. 1999 Jan;30(1):21-5 - PubMed
  15. Oncology (Williston Park). 1995 Jan;9(1):19-24; discussion 24, 27, 30 - PubMed
  16. Cancer Res. 1992 Apr 1;52(7):1974-80 - PubMed
  17. Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):547-50 - PubMed
  18. Hepatogastroenterology. 1996 May-Jun;43(9):521-6 - PubMed
  19. Cancer. 1994 Sep 1;74(5):1542-5 - PubMed
  20. J Med Invest. 1998 Aug;45(1-4):95-102 - PubMed
  21. Pathol Int. 1996 May;46(5):333-40 - PubMed
  22. Hepatology. 1995 Sep;22(3):774-9 - PubMed
  23. Liver. 1996 Apr;16(2):99-104 - PubMed
  24. Hum Pathol. 1982 Oct;13(10):874-7 - PubMed
  25. J Clin Pathol. 1994 May;47(5):453-6 - PubMed
  26. Pathol Int. 1996 Nov;46(11):908-17 - PubMed
  27. J Clin Pathol. 1990 Mar;43(3):184-92 - PubMed
  28. Hum Pathol. 2001 Aug;32(8):771-7 - PubMed
  29. Cell. 1992 Aug 21;70(4):523-6 - PubMed
  30. Cancer. 1998 Jul 15;83(2):267-75 - PubMed
  31. Cell. 1990 Jun 1;61(5):759-67 - PubMed
  32. Int J Cancer. 1991 Sep 9;49(2):196-202 - PubMed
  33. Br J Cancer. 1994 Aug;70(2):293-6 - PubMed
  34. Histopathology. 1997 Sep;31(3):226-30 - PubMed
  35. Hum Pathol. 1995 Apr;26(4):380-6 - PubMed
  36. Pathology. 1995 Apr;27(2):117-20 - PubMed
  37. J Pathol. 1993 May;170(1):67-72 - PubMed
  38. Science. 1991 Jul 5;253(5015):49-53 - PubMed
  39. Cancer Res. 1993 Feb 15;53(4):846-50 - PubMed
  40. Histopathology. 2000 Jan;36(1):54-61 - PubMed
  41. Lancet. 1990 Mar 24;335(8691):675-9 - PubMed
  42. Science. 1989 Apr 14;244(4901):217-21 - PubMed
  43. Eur J Cancer. 1997 Jun;33(7):1136-40 - PubMed

Publication Types